- Home
- CSTL vs PDT Comparison
CSTL vs PDT Comparison
Compare CSTL & PDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- PDT
- Stock Information
- Founded
- CSTL 2007
- PDT 1989
- Country
- CSTL United States
- PDT United States
- Employees
- CSTL N/A
- PDT N/A
- Industry
- CSTL Medical Specialities
- PDT Finance Companies
- Sector
- CSTL Health Care
- PDT Finance
- Exchange
- CSTL Nasdaq
- PDT Nasdaq
- Market Cap
- CSTL 661.7M
- PDT 660.6M
- IPO Year
- CSTL 2019
- PDT N/A
- Fundamental
- Price
- CSTL $33.85
- PDT $12.93
- Analyst Decision
- CSTL Strong Buy
- PDT
- Analyst Count
- CSTL 6
- PDT 0
- Target Price
- CSTL $38.67
- PDT N/A
- AVG Volume (30 Days)
- CSTL 391.5K
- PDT 145.6K
- Earning Date
- CSTL 11-03-2025
- PDT 01-01-0001
- Dividend Yield
- CSTL N/A
- PDT 8.88%
- EPS Growth
- CSTL N/A
- PDT N/A
- EPS
- CSTL N/A
- PDT N/A
- Revenue
- CSTL $343,530,000.00
- PDT N/A
- Revenue This Year
- CSTL N/A
- PDT N/A
- Revenue Next Year
- CSTL N/A
- PDT N/A
- P/E Ratio
- CSTL N/A
- PDT N/A
- Revenue Growth
- CSTL 10.15
- PDT N/A
- 52 Week Low
- CSTL $14.59
- PDT $8.77
- 52 Week High
- CSTL $35.84
- PDT $13.05
- Technical
- Relative Strength Index (RSI)
- CSTL 85.44
- PDT 35.51
- Support Level
- CSTL $23.31
- PDT $12.96
- Resistance Level
- CSTL $34.36
- PDT $13.20
- Average True Range (ATR)
- CSTL 1.46
- PDT 0.11
- MACD
- CSTL 1.10
- PDT -0.01
- Stochastic Oscillator
- CSTL 95.87
- PDT 18.15
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest growth of capital. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.